'We've Never Seen a Spike Like This'
Moncton, New Brunswick is at the centre of an alarming overdose crisis. Over the past two weeks, first responders and front-line harm reduction workers in the Greater Moncton area have been stretched thin dealing with a surge in overdoses unlike anything they've witnessed before — and investigators suspect a veterinary tranquillizer called medetomidine is to blame.
Medetomidine is a sedative commonly used in veterinary medicine to anesthetize animals. Unlike fentanyl, it doesn't respond to naloxone — the standard overdose reversal drug carried by paramedics and distributed through harm reduction programs across Canada. That's what makes this situation particularly dangerous: the usual tools aren't working the way people have come to rely on.
A Contaminant That Defeats the Standard Response
For years, naloxone has been the frontline defence against opioid overdoses. Community organizations, pharmacies, and health authorities across the country have invested heavily in naloxone distribution, and it has saved countless lives. But when medetomidine is present in the drug supply, naloxone alone may not be enough to bring someone back.
Front-line workers in Moncton say they're having to administer multiple doses of naloxone and still aren't seeing the same results. Some people are requiring additional medical intervention that goes beyond what harm reduction volunteers and paramedics can quickly provide on scene.
Health officials are urging anyone who uses drugs in the Greater Moncton area to avoid using alone, to use in smaller amounts to test for potency, and to have naloxone on hand — even if its effectiveness may be reduced. The presence of a naloxone-resistant contaminant doesn't mean the drug is useless; it may still help, especially if fentanyl is also in the mix.
A National Warning Sign
While this crisis is centred in Moncton, it's a warning sign for communities across Canada. Medetomidine has previously been detected in drug supplies in parts of the United States, and experts have long cautioned it could make its way north as illicit drug markets shift and suppliers look for cheaper cutting agents.
Canada's toxic drug supply has evolved rapidly over the past decade — from heroin to fentanyl to fentanyl analogues to now xylazine and medetomidine. Each new adulterant brings fresh challenges for health systems already strained by the overdose epidemic.
National organizations focused on drug policy and harm reduction are watching Moncton closely. If medetomidine takes hold in other Canadian cities the way fentanyl did, the country's harm reduction infrastructure will need to adapt quickly.
What Comes Next
Health authorities in New Brunswick are working to confirm the presence of medetomidine through toxicology testing and are coordinating with federal public health officials. Drug checking services — where people can bring substances to be tested before use — are being highlighted as a critical tool, though access remains limited in many parts of the country.
For now, front-line workers in Moncton are doing what they always do: showing up, responding, and trying to keep people alive with the resources they have. But the message from those on the ground is clear — this is different, and Canada needs to pay attention.
Source: CBC News
